View in EDS

In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies.

Saved in:
Bibliographic Details
Title: In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies.
Authors: Ieranò C; Microenvironment Molecular Targets, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italy., Righelli D; Statistical Sciences, University of Padua, Padua, Italy., D'Alterio C; Microenvironment Molecular Targets, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italy., Napolitano M; Microenvironment Molecular Targets, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italy., Portella L; Microenvironment Molecular Targets, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italy., Rea G; Microenvironment Molecular Targets, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italy., Auletta F; Microenvironment Molecular Targets, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italy., Santagata S; Microenvironment Molecular Targets, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italy., Trotta AM; Microenvironment Molecular Targets, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italy., Guardascione G; Microenvironment Molecular Targets, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italy., Liotti F; Institute of Endocrinology and Experimental Oncology (IEOS), CNR-NA1, Napoli, Italy., Prevete N; Institute of Endocrinology and Experimental Oncology (IEOS), CNR-NA1, Napoli, Italy.; Traslational Medical Sciences, University of Naples Federico II, Napoli, Italy., Maiolino P; Pharmacy, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italy., Luciano A; Animal Facility, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italy., Barbieri A; Animal Facility, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italy., Di Mauro A; Pathology, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italy., Roma C; Cell Biology and Biotherapy, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italy., Esposito Abate R; Cell Biology and Biotherapy, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italy., Tatangelo F; Pathology, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italy., Pacelli R; Advanced Biomedical Sciences, University of Naples Federico II, Napoli, Italy., Normanno N; Cell Biology and Biotherapy, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italy., Melillo RM; Institute of Endocrinology and Experimental Oncology (IEOS), CNR-NA1, Napoli, Italy.; Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Napoli, Italy., Scala S; Microenvironment Molecular Targets, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italy s.scala@istitutotumori.na.it.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Mar; Vol. 10 (3).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2051-1426
DOI:10.1136/jitc-2021-004032